Compare Stocks → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:CNTTFNASDAQ:DMACNASDAQ:ENLVNASDAQ:MBRXNASDAQ:SAVA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTTFCannTrust$9.60+3.0%$9.60$4.35▼$11.97$1.01B4.52528,025 shs1.43 million shsDMACDiaMedica Therapeutics$3.01-5.6%$2.80$1.67▼$4.75$114.26M1.7542,759 shs18,232 shsENLVEnlivex Therapeutics$1.50+2.7%$2.80$1.15▼$4.59$27.90M1.22153,404 shs56,816 shsMBRXMoleculin Biotech$4.64-0.6%$6.01$4.28▼$15.75$10.33M1.8530,189 shs26,696 shsSAVACassava Sciences$22.69+10.0%$21.22$12.32▼$32.10$981.34M-0.38788,414 shs1.20 million shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTTFCannTrust0.00%0.00%0.00%0.00%0.00%DMACDiaMedica Therapeutics+2.24%-8.86%+31.28%+8.32%+96.91%ENLVEnlivex Therapeutics-2.00%-6.37%-6.96%-51.40%-47.31%MBRXMoleculin Biotech-1.89%-7.34%+0.93%-38.95%-53.34%SAVACassava Sciences+1.93%-4.18%-9.36%-13.40%+9.06%Elon Musk’s Next Move Will Disrupt AI Forever (Ad)A revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTTFCannTrustN/AN/AN/AN/AN/AN/AN/AN/ADMACDiaMedica Therapeutics1.4349 of 5 stars3.52.00.00.03.60.00.0ENLVEnlivex Therapeutics3.4523 of 5 stars3.55.00.00.03.60.81.3MBRXMoleculin Biotech2.3245 of 5 stars3.53.00.00.02.70.01.3SAVACassava Sciences3.3246 of 5 stars3.50.00.04.71.80.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTTFCannTrustN/AN/AN/AN/ADMACDiaMedica Therapeutics3.00Buy$7.00132.56% UpsideENLVEnlivex Therapeutics3.00Buy$7.00366.67% UpsideMBRXMoleculin Biotech3.00Buy$35.00654.31% UpsideSAVACassava Sciences3.00Buy$124.00446.50% UpsideCurrent Analyst RatingsLatest DMAC, CNTTF, SAVA, ENLV, and MBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.004/23/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.004/12/2024ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $7.004/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/21/2024DMACDiaMedica TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.003/21/2024DMACDiaMedica TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $6.003/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.00(Data available from 5/14/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTTFCannTrust$15.96M63.54N/AN/AN/A∞DMACDiaMedica TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTTFCannTrustN/A$0.07137.1848.01N/AN/AN/AN/AN/ADMACDiaMedica Therapeutics-$19.38M-$0.56N/A∞N/AN/A-36.21%-34.45%8/12/2024 (Estimated)ENLVEnlivex Therapeutics-$29.07M-$1.56N/AN/AN/AN/A-71.00%-59.08%6/21/2024 (Estimated)MBRXMoleculin Biotech-$29.77MN/A0.00N/AN/AN/A-79.30%-64.45%8/9/2024 (Estimated)SAVACassava Sciences-$97.22M-$2.17N/A13.59N/AN/A-57.81%-52.32%8/1/2024 (Estimated)Latest DMAC, CNTTF, SAVA, ENLV, and MBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023ENLVEnlivex TherapeuticsN/A-$0.48-$0.48-$0.48N/AN/A3/20/2024N/ADMACDiaMedica Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A 2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTTFCannTrustN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTTFCannTrustN/AN/AN/ADMACDiaMedica TherapeuticsN/A18.1418.14ENLVEnlivex TherapeuticsN/A5.575.57MBRXMoleculin BiotechN/A3.863.86SAVACassava SciencesN/A9.139.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTTFCannTrust0.08%DMACDiaMedica Therapeutics10.12%ENLVEnlivex Therapeutics1.02%MBRXMoleculin Biotech15.52%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipCNTTFCannTrustN/ADMACDiaMedica Therapeutics7.20%ENLVEnlivex Therapeutics12.28%MBRXMoleculin Biotech6.70%SAVACassava Sciences12.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNTTFCannTrustN/A105.61 millionN/ANot OptionableDMACDiaMedica Therapeutics1837.96 million35.23 millionOptionableENLVEnlivex Therapeutics5018.60 million16.32 millionOptionableMBRXMoleculin Biotech182.23 million2.08 millionNot OptionableSAVACassava Sciences2943.25 million37.97 millionOptionableDMAC, CNTTF, SAVA, ENLV, and MBRX HeadlinesRecent News About These CompaniesMay 11 at 5:28 PM | bovnews.comAnalyzing Cassava Sciences Inc’s (SAVA) Stock earnings per share and revenueMay 10, 2024 | markets.businessinsider.comSAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024May 10, 2024 | bakersfield.comCassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of ...May 10, 2024 | msn.comCassava swings to Q1 profit as more patients finish simufilam phase 3 trialsMay 10, 2024 | msn.comCassava Sciences (NASDAQ:SAVA): Cracking Alzheimer’s or Succumbing to Short Sellers?May 10, 2024 | globenewswire.comCassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of SimufilamMay 10, 2024 | seekingalpha.comAnnovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's BoxMay 8, 2024 | msn.comCassava Sciences raises over $125M from warrant distributionMay 8, 2024 | globenewswire.comCassava Sciences Announces Over $125 Million Raised from Warrant DistributionMay 7, 2024 | marketbeat.comCassava Sciences (NASDAQ:SAVA) Trading Down 6.3%May 1, 2024 | msn.comCassava Sciences files for mixed shelf offeringMay 1, 2024 | msn.com27 Best Things to Do in San Francisco, CaliforniaMay 1, 2024 | msn.comCassava: The perilous past and promising future of a toxic but nourishing cropMay 1, 2024 | globenewswire.comTomorrow is Last Day to Trade SAVAW Warrants on NASDAQApril 30, 2024 | msn.comAATF launches mechanised cassava processing plant in OyoApril 30, 2024 | investorplace.comStock Market Crash Warning: Don't Get Caught Holding These 3 Biotech StocksApril 28, 2024 | msn.comExpensive sanitary pads: Agony of girls using clothes for menstruationApril 28, 2024 | smh.com.auLegal fight to save their island homes from the rising seaApril 28, 2024 | philstar.comPhilippines to endure scorching heat until mid-MayApril 27, 2024 | msn.comCenterpiece program has crashed and burnedApril 27, 2024 | msn.comHow to grow cocoyamsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCannTrustOTCMKTS:CNTTFCannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.DiaMedica TherapeuticsNASDAQ:DMACDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Enlivex TherapeuticsNASDAQ:ENLVEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
